Showing results (31-40 of 70) with videos related to
Sort By:
Pageof 7
Clinical Lung Cancer|June 18, 2015
Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24Jair Bar, Keyue Ding, Huijun Zhao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancerSimon J Crabb, Demetris Patsios, Eric Sauerbrei, et al.Investigational New Drugs|August 22, 2013
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation studyNormand Blais, D Ross Camidge, Derek J Jonker, et al.Cancer Chemotherapy and Pharmacology|October 31, 2012
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesotheliomaD Ross Camidge, Normand Blais, Derek J Jonker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2009
Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance statusGlenwood Goss, David Ferry, Rafal Wierzbicki, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2008
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials groupScott A Laurie, Isabelle Gauthier, Andrew Arnold, et al.Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology GroupScott A Laurie, Desiree Hao, Natasha B Leighl, et al.Clinical Lung Cancer|October 31, 2013
A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortiumScott A Laurie, Glenwood D Goss, Frances A Shepherd, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2009
A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortiumNatasha B Leighl, Scott A Laurie, Xueyu E Chen, et al.Cancer Chemotherapy and Pharmacology|March 8, 2013
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignanciesLaura Q M Chow, Derek I Jonker, Grace K Dy, et al.Pageof 7